Assenagon Asset Management S.A. Increases Stake in Pfizer Inc. $PFE

Assenagon Asset Management S.A. increased its holdings in Pfizer Inc. (NYSE:PFE) by 194.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,073,170 shares of the biopharmaceutical company’s stock after acquiring an additional 4,009,711 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Pfizer were worth $170,535,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Horizon Financial Services LLC lifted its position in shares of Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer in the 4th quarter worth approximately $26,000. YANKCOM Partnership bought a new position in shares of Pfizer during the 4th quarter worth approximately $28,000. HFM Investment Advisors LLC raised its stake in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares in the last quarter. Finally, Abound Financial LLC purchased a new stake in Pfizer during the fourth quarter valued at approximately $31,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer won FDA approval for an expanded IBRANCE regimen in metastatic breast cancer, a meaningful commercial and pipeline win for its oncology franchise.
• Positive Sentiment: The company advanced a pediatric pneumococcal “catch-up” vaccine into Phase 3, adding another potential growth catalyst to the pipeline.
• Positive Sentiment: Pfizer declared a $0.43 third-quarter dividend, extending its long streak of quarterly payouts and supporting the stock’s income profile.
• Neutral Sentiment: Pfizer reaffirmed its FY 2026 outlook despite leadership change chatter, which may help reassure investors but does not materially change the near-term growth story.
• Negative Sentiment: Sigvotatug vedotin missed its primary survival goal in Phase 3 lung cancer testing, renewing concerns about Pfizer’s oncology pipeline momentum and contributing to the stock’s weakness. Article Title

Pfizer Stock Down 2.7%

NYSE:PFE opened at $24.05 on Thursday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a twelve month low of $23.11 and a twelve month high of $28.75. The company has a market cap of $137.07 billion, a PE ratio of 18.36 and a beta of 0.34. The company’s 50 day moving average is $26.07 and its two-hundred day moving average is $26.31.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter last year, the company posted $0.92 earnings per share. The business’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were paid a $0.43 dividend. The ex-dividend date was Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. CICC Research assumed coverage on shares of Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target on the stock. Cantor Fitzgerald reiterated a “neutral” rating on shares of Pfizer in a report on Monday, June 1st. Bank of America lowered their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Guggenheim boosted their target price on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Finally, Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $28.82.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.